Alpha Cognition Inc. (ACOG) vs Coherus Oncology, Inc. (CHRS)

Alpha Cognition Inc. and Coherus Oncology, Inc. are both Biotechnology companies. Alpha Cognition Inc. and Coherus Oncology, Inc. are of similar size ($186.6M and $183.9M). Alpha Cognition Inc. has the higher net margin (−137.7% vs −259.4%) and the lower return on invested capital (−144.7% vs 0.00%). Across the 17 metrics below, Alpha Cognition Inc. leads on 10 and Coherus Oncology, Inc. on 7.

Valuation

Metric ACOG CHRS Biotechnology median
P/E n/m n/m 7.88
P/S 12.08 3.43 11.47
P/B 3.48 2.88 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 9.44 5.53 10.73
Earnings yield (12.75%) (91.15%) (28.84%)
Free cash flow yield (20.11%) (106.88%) (23.03%)

Profitability

Metric ACOG CHRS Biotechnology median
Gross margin 90.37% 68.94% 65.16%
Operating margin (174.70%) (311.56%) 0.00%
Net margin (137.69%) (259.41%) 0.00%
Free cash flow margin (242.99%) (365.22%) 0.00%
Return on equity (49.53%) (146.27%) (57.72%)
Return on assets (38.33%) (41.90%) (49.22%)
Return on invested capital (144.65%) 0.00% 0.00%

Growth

Metric ACOG CHRS Biotechnology median
Revenue growth (TTM) — 61.00% 5.64%
EPS growth (last fiscal year) 42.08% 472.00% —
Revenue growth, 5-year CAGR — (38.41%) 8.40%
Net income growth, 5-year CAGR 0.00% 4.91% 0.00%

Health

Metric ACOG CHRS Biotechnology median
Debt to equity 0.00 0.61 0.00
Current ratio 9.03 1.77 4.73
Net debt to EBITDA 2.92 0.76 0.96

Dividend

Metric ACOG CHRS Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric ACOG CHRS Biotechnology median
Market cap 186.64m 183.86m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack